[go: up one dir, main page]

MX2017004684A - Compuestos neuroactivos y metodos de uso de los mismos. - Google Patents

Compuestos neuroactivos y metodos de uso de los mismos.

Info

Publication number
MX2017004684A
MX2017004684A MX2017004684A MX2017004684A MX2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A
Authority
MX
Mexico
Prior art keywords
methods
neuroactive compounds
sterol
disorder
lemli
Prior art date
Application number
MX2017004684A
Other languages
English (en)
Other versions
MX388694B (es
Inventor
Martinez Botella Gabriel
C Quirk Michael
J Doherty James
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2017004684A publication Critical patent/MX2017004684A/es
Publication of MX388694B publication Critical patent/MX388694B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan métodos para tratar un paciente que padece de un trastorno de síntesis de esterol o un trastorno de deficiencia de esterol, por ejemplo, síndrome Smith-Lemli-Opitz, el método comprende administrar al sujeto una cantidad efectiva de un compuesto que modula el receptor NMDA.
MX2017004684A 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos. MX388694B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07
PCT/US2015/054551 WO2016057713A1 (en) 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2017004684A true MX2017004684A (es) 2017-06-30
MX388694B MX388694B (es) 2025-03-20

Family

ID=55653736

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004684A MX388694B (es) 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos.
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US20170304321A1 (es)
EP (1) EP3204011A4 (es)
JP (3) JP2017530982A (es)
KR (1) KR20170065637A (es)
CN (2) CN112121171A (es)
AU (2) AU2015330906A1 (es)
BR (1) BR112017007053A2 (es)
CA (1) CA2963938C (es)
IL (2) IL292465B2 (es)
MX (2) MX388694B (es)
MY (1) MY202135A (es)
PE (1) PE20170907A1 (es)
PH (1) PH12017500639A1 (es)
RU (1) RU2764702C2 (es)
SG (2) SG10202011773UA (es)
WO (1) WO2016057713A1 (es)
ZA (1) ZA201702545B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202300232T1 (it) 2011-09-08 2023-09-06 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e relativi usi
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
IL294448A (en) 2013-12-24 2022-09-01 Univ Virginia Commonwealth Uses of oxidized cholesterol sulfates
WO2015195967A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017007832A1 (en) * 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289971C1 (en) 2015-07-06 2022-12-08 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
BR122021005552B1 (pt) 2015-07-06 2024-01-02 Sage Therapeutics, Inc Compostos oxiesteróis, seus usos e composição farmacêutica
EP3436022B1 (en) 2016-04-01 2022-03-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PT3481846T (pt) 2016-07-07 2021-08-13 Sage Therapeutics Inc 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
KR102593667B1 (ko) 2016-08-02 2023-10-24 버지니아 커먼웰스 유니버시티 5-콜레스텐-3, 25-디올, 3-술페이트 (25hc3s) 또는 이의 약학적으로 허용 가능한 염, 및 적어도 하나의 시클릭 올리고당을 포함하는 조성물
WO2018064649A1 (en) 2016-09-30 2018-04-05 Sage Therapeutics, Inc. C7 substituted oxysterols and methods as nmda modulators
RU2019115112A (ru) 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
RU2019115113A (ru) * 2016-10-18 2020-11-24 Сейдж Терапьютикс, Инк. Оксистеролы и способы их применения
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
JP2011502974A (ja) * 2007-11-06 2011-01-27 ナームローゼ・フエンノートチヤツプ・オルガノン ヒトにおけるホルモン抑制の方法
EP2296658A4 (en) * 2008-05-09 2014-01-15 Univ Emory NMDA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPSYCHIATRIC ILLNESSES
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2010088414A2 (en) * 2009-01-28 2010-08-05 Emory University Subunit selective nmda receptor potentiators for the treatment of neurological conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
SMT202300232T1 (it) * 2011-09-08 2023-09-06 Sage Therapeutics Inc Steroidi neuroattivi, composizioni e relativi usi
EP2841067A4 (en) * 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
JP6419087B2 (ja) * 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
AU2014243773B2 (en) 2013-03-13 2018-12-13 Sage Therapeutics, Inc. Neuroactive steroids and methods of use thereof
HK1220472A1 (zh) * 2013-03-13 2017-05-05 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2015195967A1 (en) * 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
EP3166613A4 (en) * 2014-07-09 2018-02-21 Duke University Compositions and methods for the repair of myelin
WO2017007832A1 (en) * 2015-07-06 2017-01-12 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
AU2021200721A1 (en) 2021-03-04
JP2017530982A (ja) 2017-10-19
BR112017007053A2 (pt) 2018-06-19
SG10202011773UA (en) 2021-01-28
RU2017115849A3 (es) 2019-05-15
CA2963938A1 (en) 2016-04-14
EP3204011A1 (en) 2017-08-16
JP2020196759A (ja) 2020-12-10
EP3204011A4 (en) 2018-06-20
CN107405352A (zh) 2017-11-28
NZ730862A (en) 2024-01-26
US20170304321A1 (en) 2017-10-26
IL292465B2 (en) 2025-06-01
KR20170065637A (ko) 2017-06-13
IL251505B (en) 2022-05-01
WO2016057713A1 (en) 2016-04-14
IL251505A0 (en) 2017-05-29
JP2022033285A (ja) 2022-02-28
PE20170907A1 (es) 2017-07-12
SG11201702799UA (en) 2017-05-30
US20230218638A1 (en) 2023-07-13
IL292465A (en) 2022-06-01
MX388694B (es) 2025-03-20
AU2021200721B2 (en) 2023-06-01
MY202135A (en) 2024-04-05
CN112121171A (zh) 2020-12-25
ZA201702545B (en) 2019-06-26
IL292465B1 (en) 2025-02-01
RU2017115849A (ru) 2018-11-13
AU2015330906A1 (en) 2017-04-27
MX2021011939A (es) 2021-11-03
RU2764702C2 (ru) 2022-01-19
PH12017500639A1 (en) 2017-09-25
CA2963938C (en) 2023-10-24

Similar Documents

Publication Publication Date Title
MX2017004684A (es) Compuestos neuroactivos y metodos de uso de los mismos.
SV2018005709A (es) 3-azabiciclo[3.1.0]hexanos sustituidos como inhibidores de cetohexoquinasa
CY1121675T1 (el) Διαμορφωτες υποδοχεων nmdα σπeipο-λακταμης και χρησεις αυτων
BR112018004620A2 (pt) moduladores da expressão de kras
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
NZ732246A (en) Hydroxy containing fxr (nr1h4) modulating compounds
CL2016000378A1 (es) Composiciones y métodos terapéuticos para la regresión acelerada de placa
BR112018072663A2 (pt) moduladores da via integrada ao estresse
CU20160185A7 (es) Compuestos de heteroarilo para la inhibición de cinasa
MX2017007522A (es) Compuestos moduladores del receptor x farnesoide (frx) (receptor nr1h4) novedosos.
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
BR112017024555A2 (pt) moduladores de ccr2
EP4219718A3 (en) Compositions and methods for modulating complement factor b expression
WO2016100619A3 (en) Treatment and diagnosis of cancer
CY1122469T1 (el) Υπογλωσσια φαρμακοτεχνικη μορφη ριλουζολης
BR122020024446B8 (pt) Compostos para modulação da expressão do receptor do hormônio de crescimento
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112017012381A2 (pt) imunoterapia para doença angiogênica
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
MY181685A (en) Methods and compositions comprising ursolic acid and/or resveratrol for treating obesity, diabetes, or cancer